StockNews.AI
VNRX
StockNews.AI
92 days

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

1. VNRX publishes study on nucleosomes in healthy cats, boosting cancer screening potential. 2. First study to detect nucleosome levels in cats, enhancing product development for feline cancer. 3. Sixty million U.S. cats offer significant commercial opportunity for Volition's Nu.Q® products. 4. Target product for feline lymphoma confirms early detection and monitoring importance. 5. Research supports optimal sample collection protocols vital for testing advancements.

9m saved
Insight
Article

FAQ

Why Bullish?

The study’s findings open a large market for VNRX's cat-focused diagnostic tools, particularly for feline lymphoma. Historical data shows that innovations in veterinary diagnostics often lead to stock price increases, especially when entering a large addressable market like the estimated 60 million U.S. cats.

How important is it?

The potential market size for feline cancer screening aligns directly with VNRX's strategic goals, making this information critically relevant for investors and stakeholders. The publication of this research enhances VNRX's credibility in veterinary diagnostics, indicating its progress towards diversification and revenue generation.

Why Long Term?

The implications of this study will take time to manifest in sales, as product development and market adoption typically take years. However, establishing a foothold in veterinary oncology could provide sustained revenue growth over the long term.

Related Companies

IDEXZTSPETQ
Clinical Paper Published in BMC Veterinary Research , /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer. Frederic Wuilque, Vice President, Global Products, said: "This is an essential step in the development of Nu.Q® products for cats, our third species. This opens up the potential for cancer screening and monitoring in cats, representing a significant annual commercial opportunity for Volition. There are more than 60 million cats in the U.S. alone, 25% of which are "senior" cats and therefore suitable for an annual check1. "This important study confirms that H3.1 nucleosomes can be successfully quantified from blood obtained from healthy cats and presents data regarding an optimal collection and processing protocol. Additionally, it supports the use of EDTA tubes when collecting samples for nucleosome testing in cats.  "Our first target product is for feline lymphoma, the most common cause of cancer in cats2. We are delighted to have completed the pre-analytics work for feline and confirm that the enrolment for patients for our clinical study for the detection of feline lymphoma has been underway for several months. We look forward to presenting the findings of our Nu.Q® Vet assay in this much needed area  upon study completion." About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.   The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries:Louise Batchelor, Volition, [email protected] +44 (0)7557 774620 Investor Relations:Jeremy Feffer, LifeSci Advisors, [email protected] +1-212-915-2568 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. 1. Data on File. Volition Total Accessible Market Model. 2. Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019. SOURCE VolitionRx Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News